Читать книгу Recent Advances in Dialysis Therapy in Japan - Группа авторов - Страница 106

1Riminucci M, Collins MT, Fedarko NS, et al: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683–692.

2Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD: Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006;291:E38–E49.

3Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K: Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009;45:1161–1168.

4Urakawa I, Yamazaki Y, Shimada T, et al: Klotho converts canonical FGF23 receptor into a specific receptor for FGF23. Nature 2006;444:770–774.

5Shimada T, Urakawa I, Yamazaki Y, et al: FGF23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004;314:409–414.

6Shimada T, Hasegawa H, Yamazaki Y, et al: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429–435.

7Hasegawa H, Nagano N, Urakawa I, et al: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010;78:975–980.

8Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003–4008.

9Wetmore JB, Quarles LD: Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol 2009;5:24–33.

10Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.

11Gutierrez O, Isakova T, Rhee E, et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205–2215.

12Imanishi Y, Inaba M, Nakatsuka K, et al: FGF23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943–1946.

13Weber TJ, Liu S, Indridason OS, Quarles LD: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003;18:1227–1234.

14Gutierrez OM, Mannstadt M, Isakova T, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584–592.

15Kendrick J, Cheung AK, Kaufman JS, et al: FGF23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011;22:1913–1922.

16Gutierrez OM, Januzzi JL, Isakova T, et al: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545–2552.

17Faul C, Amaral AP, Oskouei B, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393–4408.

18Guideline Working Group, Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-525.

19Finch JL, Tokumoto M, Nakamura H, et al: Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010;298:F1315–F1322.

20Saji F, Shigematsu T, Sakaguchi T, et al: Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010;299:F1212–F1217.

21Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L: Change in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2012;27:2263–2269.

22Sprague SM, Wetmore JB, Gurevich K, et al: Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2015;10:1021–1030.

23Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008;74:1070–1078.

24Shoji T, Shinohara K, Kimoto E, et al: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in haemodialysis population. Nephrol Dial Transplant 2004;19:179–184.

Masaki Ohya, MD, PhD

Division of Nephrology, Department of Internal Medicine

Wakayama Medical University

811-1 Kimiidera, Wakayama 641-8509 (Japan)

E-Mail m-ohya@wakayama-med.ac.jp